No Data
No Data
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Hold Rating
Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations
Express News | Guggenheim Reiterates Buy on Beam Therapeutics, Maintains $78 Price Target
BMO Capital Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $57
Beam Therapeutics Analyst Ratings
sooogod : nbis.
GOGOY : Tem will be the next